Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GSK 
GlaxoSmithKline PLC ADR (GSK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/24/2025: GSK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 1.41% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/24/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 76.96B USD | Price to earnings Ratio 23.52 | 1Y Target Price 43.42 |
Price to earnings Ratio 23.52 | 1Y Target Price 43.42 | ||
Volume (30-day avg) 5171474 | Beta 0.29 | 52 Weeks Range 31.37 - 44.37 | Updated Date 04/2/2025 |
52 Weeks Range 31.37 - 44.37 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 4.11% | Basic EPS (TTM) 1.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.21% | Operating Margin (TTM) 12.28% |
Management Effectiveness
Return on Assets (TTM) 6.53% | Return on Equity (TTM) 22.8% |
Valuation
Trailing PE 23.52 | Forward PE 8.62 | Enterprise Value 94044881221 | Price to Sales(TTM) 2.45 |
Enterprise Value 94044881221 | Price to Sales(TTM) 2.45 | ||
Enterprise Value to Revenue 2.32 | Enterprise Value to EBITDA 10.9 | Shares Outstanding 2032220032 | Shares Floating 3947946444 |
Shares Outstanding 2032220032 | Shares Floating 3947946444 | ||
Percent Insiders 0.06 | Percent Institutions 17.03 |
Analyst Ratings
Rating 3.57 | Target Price 45.07 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold 3 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GlaxoSmithKline PLC ADR
Company Overview
History and Background
GlaxoSmithKline (GSK) was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. Its roots trace back to the 18th and 19th centuries. Significant milestones include the development of key vaccines and pharmaceuticals, and strategic acquisitions to expand its portfolio.
Core Business Areas
- Pharmaceuticals: Develops and markets a range of prescription medicines, focusing on respiratory, HIV, oncology, and immunology.
- Vaccines: Develops and distributes vaccines for various diseases, including influenza, meningitis, and shingles.
Leadership and Structure
GSK is led by a Chief Executive Officer (CEO) and a board of directors. The organizational structure includes global business units responsible for pharmaceuticals and vaccines, supported by central functions like R&D and commercial operations.
Top Products and Market Share
Key Offerings
- Shingrix: A vaccine for shingles. Generated significant revenue. Competitors: Merck's Zostavax (discontinued).
- Duvroq: A medicine for HIV. Competitors: Gilead's Biktarvy.
- Arexvy: A vaccine for RSV. Competitors: Pfizer's Abrysvo and Moderna's mRNA-1345.
Market Dynamics
Industry Overview
The pharmaceutical and vaccine industry is characterized by high R&D costs, stringent regulatory requirements, and increasing competition from generic and biosimilar manufacturers. The industry is driven by innovation and global health needs.
Positioning
GSK is a major player in the global pharmaceutical and vaccine market, with a strong presence in respiratory, HIV, and vaccines. Its competitive advantages include a diverse product portfolio, a strong R&D pipeline, and a global distribution network.
Total Addressable Market (TAM)
The global pharmaceuticals market is multi-trillion dollars in TAM. GlaxoSmithKline PLC ADR maintains a strong position within various segments such as vaccines.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Global presence
- Diverse product portfolio
- Established brand reputation
Weaknesses
- Dependence on key products
- Exposure to patent expirations
- High R&D costs
- Legal and regulatory risks
Opportunities
- Emerging markets growth
- Development of novel therapies
- Strategic partnerships and acquisitions
- Increasing demand for vaccines
Threats
- Generic competition
- Biosimilar competition
- Pricing pressures
- Regulatory changes
Competitors and Market Share
Key Competitors
- PFE
- MRK
- JNJ
- NVS
- ABBV
Competitive Landscape
GSK faces intense competition from major pharmaceutical companies. While GSK has a strong vaccine portfolio, other players such as Pfizer have larger overall market share due to oncology portfolios.
Major Acquisitions
Affinivax
- Year: 2022
- Acquisition Price (USD millions): 2100
- Strategic Rationale: GSK acquired Affinivax to strengthen its vaccine pipeline with a novel pneumococcal vaccine candidate.
Growth Trajectory and Initiatives
Historical Growth: Historical growth unavailable. Replace with concrete metrics from a recent financial statement.
Future Projections: Future projections unavailable. Replace with concrete metrics from a recent financial statement.
Recent Initiatives: Recent strategic initiatives unavailable. Replace with concrete metrics from a recent financial statement.
Summary
GSK is a major player in the pharmaceutical and vaccine industry, but faces competitive pressures from larger competitors. The company has a strong vaccine portfolio. They need to focus on maintaining a diverse portfolio and strengthening their financials while dealing with patent expirations, regulatory approvals, and competitors like Pfizer, Johnson and Johnson and Merck.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlaxoSmithKline PLC ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 1986-07-09 | CEO & Director Ms. Emma Natasha Walmsley | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 68629 | Website https://www.gsk.com |
Full time employees 68629 | Website https://www.gsk.com | ||
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.